Article Text

Download PDFPDF
What Surveillance Plan Should Be Advised for Patients in Remission After Completion of First-Line Therapy for Advanced Ovarian Cancer?
  1. Gordon J. S. Rustin, MD, MSc, FRCP
  1. Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
  1. Address correspondence and reprint requests to Gordon J. S. Rustin, Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex HA6 2RN, UK. E-mail: grustin{at}


Based on the results of the Medical Research Council OVO5/European Organisation for Research and Treatment of Cancer 55955 trial, the follow-up plan I recommend for patients in remission after completion of first-line therapy for advanced ovarian cancer is appointments: every 3 months for 2 years, every 4 months on the third year, then every 6 months thereafter, and discharge if no relapse by 10 years. History and examination (not internal) should be performed at each appointment. CA-125 should only be measured if there is a suspicion of relapse or at patient's request. No scans should be performed unless clinical indication or rising CA-125.

  • CA-125
  • Follow-up
  • Ovarian cancer
  • Surveillance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.